商业保险女性宫颈癌初始治疗的医疗费用
基于MarketScan数据库2008至2016年记录,分析4495例新诊断宫颈癌的商业保险女性患者,其中手术组3014例(67%)、放疗组1481例(33%)。诊断后第一年人均总支出中位数为56,250美元,手术组37,222美元、放疗组101,266美元;人均自付费用中位数为2,253美元,占总费用的3.9%。
要点
- 诊断后第一年人均总支出中位数为56,250美元(四分位距25,767–107,532美元)。
- 以放疗为主要治疗者人均总支出中位数101,266美元,高于手术者的37,222美元。
- 人均自付费用中位数2,253美元,约占总费用的3.9%。
核心结论
- 新诊断宫颈癌女性的医疗费用可观,患者以自付形式承担约3.9%的费用。
研究设计与样本
- 基于MarketScan数据库2008至2016年记录,纳入接受商业保险且新诊断宫颈癌的女性,按主要治疗分为手术(子宫切除术伴或不伴辅助放疗或化疗)或放疗两组,估算自首次治疗日起12个月经通胀调整的医疗支出。
主要发现
- 共纳入4495例患者,其中手术组3014例(67%)、放疗组1481例(33%)。
- 诊断后第一年人均总支出中位数为56,250美元(四分位距25,767–107,532美元)。
- 手术组人均总支出中位数为37,222美元(四分位距20,957–75,555美元),放疗组为101,266美元(四分位距63,155–160,760美元)。
- 手术组住院服务支出中位数为15,145美元(四分位距0–26,898美元),门诊服务为18,430美元(四分位距5,354–48,047美元),门诊药房为628美元(四分位距141–1,847美元)。
- 未需辅助治疗者费用中位数为26,164美元,接受辅助放疗者为89,760美元;全队列自付费用中位数为2,253美元(四分位距1,137–3,990美元),占总费用的3.9%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with newly diagnosed cervical cancer are often treated with extensive, multimodal therapies that may include a combination of surgery, radiation, and chemotherapy. Little is known about the cost of treatment or how these costs are passed on to the patients. OBJECTIVE: The objectives of this study were to examine the cost of care during the first year after a diagnosis of cervical cancer, to estimate the sources of the costs, and to explore the out-of-pocket costs. STUDY DESIGN: We performed a study of women with commercial insurance who received a new diagnosis of cervical cancer, and whose cases were recorded in the MarketScan database from 2008 to 2016. Patients were categorized based on the primary treatment received being either surgery (hysterectomy with or without adjuvant radiation or chemotherapy) or radiation. The inflation-adjusted medical expenditures for a 12-month period beginning on the date of the first treatment were estimated. The payments were divided into the expenditures of inpatient care, outpatient care (including chemotherapy), and outpatient pharmacy costs. The out-of-pocket costs incurred by the patients in the form of copayments, coinsurance, and deductibles were estimated. RESULTS: A total of 4495 patients, including 3014 (67%) who underwent surgery and 1481 (33%) who primarily underwent radiotherapy, were identified. The median total expenditure per patient during the first year after the diagnosis was $56,250 (interquartile range, $25,767-$107,532). The median total expenditure for patients with surgery as the primary treatment was $37,222 (interquartile range, $20,957-$75,555). The median total expenditure for patients treated primarily with radiotherapy was $101,266 (interquartile range, $63,155-$160,760). For patients treated primarily with surgery, inpatient services accounted for $15,145 (interquartile range, $0-$26,898), outpatient services accounted for $18,430 (interquartile range, $5354-$48,047), and outpatient pharmacy costs accounted for $628 (interquartile range, $141-$1847). The median cost for those women who did not require adjuvant therapy was $26,164 compared with $89,760 for women treated with adjuvant radiation. The median out-of-pocket costs for the cohort was $2253 (interquartile range, $1137-$3990) or 3.9% of the total costs. CONCLUSION: The cost of care for women with newly diagnosed cervical cancer is substantial. Overall, patients are responsible for approximately 3.9% of the costs in the form of out-of-pocket expenditures.
引用
- Blanco M, Chen L, Melamed A, et al. Cost of care for the initial management of cervical cancer in women with commercial insurance. Am J Obstet Gynecol. 2020. PMID: 32818476. doi:10.1016/j.ajog.2020.08.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。